Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Victoria's Secret & Co (VSXY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Victoria's Secret & Co — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Victoria's Secret & Co trades at $86.8 (market cap $7.08B). The key difference: Victoria's Secret & Co is far larger — about 7.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Victoria's Secret & Co is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Victoria's Secret & Co for 34 Days on average.
| MRVI | VSXY | |
|---|---|---|
Market Cap | $972.90M | $7.08B |
Volume | 4,325,710 | 1,247,026 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $99.97 |
52-Week Low | $2.83 | $30.19 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $1.08B | $9.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Victoria's Secret (VSXY) trades at $88.39, down 0.23% today, with a bullish technical signal supported by moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and projected 2026 revenue growth to $6.9B. Recent news highlights brand momentum through fashion show expansion and omnichannel retail strategy, though valuation remains elevated at P/E 19.83 and P/B 7.16.
The outlook appears positive with 60% analyst buy ratings and projected net income growth to $378M in 2026. Key opportunities include international expansion and margin improvement, while risks involve rich valuation, rising costs, and competitive pressures in retail apparel. The stock trades near consensus target of $86.80 with upside potential to $101.00.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Victoria's Secret & Co
Victoria's Secret & Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime.
Read more on VSXY →
